The Risks and Benefits of Myopia Control
What Myopia Control Actually Does
Myopia control is a set of treatments aimed at slowing how fast a child's eyes grow. Children with myopia, or nearsightedness, have eyes that keep getting longer from front to back. That growth is what makes the prescription get stronger each year. By slowing eye growth, we reduce the final prescription the child ends up with as an adult. A lower final number is what protects the retina decades later.
Standard glasses correct today's blur. They do not slow tomorrow's growth. Myopia control tools work in a different way. They change how light lands on the peripheral retina. That is the signal the eye uses to decide whether to keep growing. These tools include low-dose atropine drops, soft multifocal contacts, overnight ortho-k lenses, and specialty glasses. Each one targets the same growth signal through a different path.
Myopia control is a recent option in routine pediatric eye care. The 2022 American Academy of Ophthalmology Preferred Practice Pattern on refractive errors now lists it as part of myopia care. That guideline names atropine, ortho-k, soft multifocal contacts, and specialty glasses as proven options. Parents who wore glasses in the 1990s may not have been offered any of these. The clinical landscape has shifted in one generation.
A myopia control visit is longer than a routine eye exam. It includes a cycloplegic refraction for an accurate reading. It also includes an axial-length measurement to set a baseline. The clinician then talks through lifestyle, family history, and treatment choices. After that, the clinician proposes a plan. That plan may combine an optical treatment with a drop. Or it may start with lifestyle changes for a child progressing slowly.
Why Slowing Myopia Matters for Long-Term Eye Health
Myopia is becoming far more common worldwide. Projections cited by the American Academy of Ophthalmology in 2023 estimate global myopia prevalence will reach about 50 percent by 2050. That means half the world is expected to be nearsighted within a generation. High myopia, defined as -6.00 diopters or worse per the AAO, is projected to rise to about 10 percent over the same window. That trend is what pushed myopia control into mainstream pediatric care.
A stronger final prescription is not just an optical shop issue. Per the American Academy of Ophthalmology (2023), high myopia raises lifetime risk for retinal detachment, myopic maculopathy, glaucoma, and earlier cataract. The longer the eye, the thinner the retinal tissue. That tissue is more prone to breaks, tears, and scarring. These are the conditions that can cause vision loss later in life.
The benefit of slowing progression is not all or nothing. Per the AAO, slowing progression by even 1 diopter meaningfully reduces lifetime risk of myopic maculopathy. That is a practical frame for parents. The goal is not to stop myopia entirely. The goal is to end up a few diopters lower than the child would have reached without treatment. Those saved diopters translate into lower disease risk.
Family history is a strong predictor of childhood myopia. EyeWiki (2023) reports that children with two myopic parents have roughly 3 to 6 fold increased odds of becoming myopic compared with children of non-myopic parents. Environment layers on top of genetics. Heavy near work and low outdoor time both speed up the process. Children with two myopic parents who spend most afternoons indoors benefit most from early action.
Treatment Options Used for Myopia Control
Low-dose atropine is an eye drop used at bedtime. The strengths used for myopia control are much weaker than the dilating drops used in clinic. Compounding pharmacies prepare them in the range of 0.01 percent to 0.05 percent. Atropine works through paths that are still being studied. The paths clearly involve the retina's growth-signaling system.
Orthokeratology, or ortho-k, uses rigid lenses worn only at night. The lens gently reshapes the front of the cornea. That reshaping corrects the child's vision for the next day. The child wakes up, takes the lens out, and goes to school without daytime contacts or glasses. The same reshaping also shifts peripheral retinal focus. That shift helps slow eye growth.
Soft multifocal contacts for myopia control are daily disposable lenses. They use a design that places myopic defocus on the peripheral retina. One brand of daily disposable soft contact lens received FDA approval in 2019 as the first and only U.S. FDA-approved contact lens indicated to slow myopia progression in children, for an initial fitting age range of 8 to 12 years. Other soft multifocal designs are used off-label with similar intent.
Specialty myopia-control spectacle lenses are the newest optical option. They use small lenslets or diffusion patches across the lens surface. Those features create peripheral myopic defocus while keeping central vision clear. For children who cannot tolerate contacts or drops, these glasses offer a glasses-only path to myopia control.
Clinicians sometimes combine treatments when one is not doing enough. A common combination pairs low-dose atropine with a soft multifocal contact or with ortho-k. Combination therapy is usually considered when axial length keeps growing quickly. That is judged after the child has been on the first-line treatment at full adherence.
The Measurable Benefits of Treatment
The Low-Concentration Atropine for Myopia Progression study, known as LAMP, compared atropine strengths in children. The LAMP study (2019) found that 0.05 percent atropine reduced spherical-equivalent myopia progression by roughly 67 percent compared with placebo at one year. Lower strengths showed smaller but still useful effects. Lower strengths also had fewer side effects. Those data shaped the current preference for starting in the 0.01 percent to 0.05 percent range.
Ortho-k has been studied in randomized trials across many countries. Per EyeWiki (2023), orthokeratology slows axial elongation by approximately 30 to 50 percent compared with single-vision controls in randomized trials. Children often value the added benefit of lens-free daytime vision. That matters for school, sports, and swimming. Quality of life and progression-slowing can both improve with this option.
Pivotal data supporting FDA approval came from a three-year randomized trial. That trial enrolled children who started treatment between ages 8 and 12. It showed meaningful slowing of both refractive progression and axial growth. That is why the lens carries a specific myopia-control indication. Post-approval studies continue to track outcomes past the three-year window.
Trial efficacy numbers describe group averages. Individual children respond in different ways. Some slow more than the trial average. Others slow less. The clinician tracks axial length over time to judge the specific child's response. That is why axial biometry is part of follow-up, not just repeat refraction.
The Risks and Side Effects Families Should Know
Ortho-k raises the risk of microbial keratitis, a corneal infection. Any overnight rigid lens wear raises that risk above daytime-only wear. Per EyeWiki (2023) on orthokeratology, strict hygiene and prompt evaluation of any pain, redness, or vision change are essential to avoid vision loss. Families choosing ortho-k commit to a cleaning and handling routine. They also agree to call the office the same day if a red or painful eye appears.
Low-dose atropine can cause photophobia and near blur. Photophobia means light sensitivity. Atropine relaxes the focusing muscle and dilates the pupil. Per EyeWiki (2023) on atropine for myopia, these side effects are dose-dependent and less common at 0.01 percent than at 0.05 percent. Some children need photochromic lenses or sunglasses to stay comfortable outdoors. Allergic reaction is less common but possible. Treatment is paused and reviewed if the child has redness or itching after each drop.
Soft multifocal contacts and specialty glasses have their own adjustment period. Children may report mild blur or haze in the first weeks. That happens as the brain adapts to the peripheral defocus zones. Most adapt within a few weeks. A small number never fully tolerate the optics and need to switch approaches.
Every myopia-control treatment involves more clinic visits than standard glasses. Adherence matters. A drop skipped or a lens not worn does not slow growth that night. Families weigh the time and out-of-pocket cost against the long-term benefit. Cost considerations vary by insurance and by the treatment chosen. That conversation is part of the consultation.
Who Is a Candidate for Myopia Control
A clear candidate is a child whose prescription moved a lot in a year. The AAO Preferred Practice Pattern (2022) flags progression greater than -0.50 diopters per year, axial growth above age norms, family history of high myopia, or early onset of myopia as reasons to refer for a myopia-control consultation. These children face the highest risk of reaching high myopia in adulthood if untreated.
Earlier onset tends to predict a higher final prescription. The eye has more growing years ahead. Per the National Eye Institute (2022), early age of onset is a recognized risk factor. Others include having one or both myopic parents, heavy near work, and limited time outdoors. A child first diagnosed at age six warrants a different plan than a child first diagnosed at age fourteen.
A child with a mild current prescription may still warrant a myopia-control talk. That is true if both parents are highly myopic and the child spends most of the week indoors. The clinician weighs all of these inputs. Starting earlier in a higher-risk child tends to produce a better final outcome than waiting for rapid change to appear.
Not every nearsighted child needs myopia control. A child with stable mild myopia, no family history of high myopia, and healthy outdoor habits can be tracked with yearly exams. The purpose of the consult is to match the intervention to the level of risk. Sometimes the plan is watchful waiting with lifestyle reinforcement.
How Clinicians Diagnose Myopia and Track Progression
The AAO Preferred Practice Pattern on refractive errors (2022) recommends cycloplegic refraction as the standard of care for accurate myopia measurement in children. The reason is that accommodation can produce false or variable myopia on non-cycloplegic testing. Cycloplegic drops briefly relax the focusing muscle. The measurement then reflects the true refractive state of the eye. This step matters most at the first visit, when a baseline must be set.
Optical biometry uses non-contact infrared light. It measures how long the eyeball is from cornea to retina. Per EyeWiki (2023), optical biometry is the preferred objective method to track myopia progression over time. Unlike refraction, axial length is not affected by accommodation. That produces a cleaner year-over-year progression curve. A child whose refraction looks stable but whose axial length is still growing is still progressing.
Children rarely complain of myopia in clear words. Instead, families notice the child squinting at the television. Or sitting close to screens. Or missing the chalkboard. Or holding books close to the face. Per the American Academy of Ophthalmology (2023), myopia presents with blurred distance vision that is corrected by minus-powered lenses. In children, the picture often includes these behavioral clues before the child puts the blur into words.
Once treatment begins, follow-up visits repeat refraction and axial biometry at set intervals. The clinician compares the child's path to expected growth curves for untreated peers. When the path flattens, the treatment is working. When it does not, the clinician reconsiders dose, lens design, or adds a second treatment.
Lifestyle Habits That Support Myopia Control
Outdoor time is the most studied lifestyle factor in myopia prevention. The AAO (2023) recommends at least 1 to 2 hours of outdoor time daily for children as a zero-cost, evidence-backed strategy to reduce myopia onset risk. The likely path involves bright natural light and retinal dopamine. That signal helps slow axial growth. This habit is added on top of any medical treatment, not used to replace one.
Heavy close work is a recognized risk factor per the National Eye Institute (2022). Helpful habits include breaking near work with distance views, keeping a safe reading distance, and avoiding long single-session screen use. These changes may not reverse existing myopia. They do help slow the pace, especially alongside a prescribed treatment.
Steady sleep and a balanced diet support a child's overall eye health. Managing any other health issue helps too. No single food or supplement has been proven to slow myopia. Families should be wary of products that make that claim. The habits that help are the same ones that help general pediatric health.
Habits only help when the family can keep them up. A child whose parents both work long hours needs a plan that fits the real schedule. That might mean outdoor time before school, after-school programs outside, or weekend-heavy strategies. The clinician works with families to build a plan that will survive the first month.
When to See an Eye Doctor About Myopia Control
Families should book an eye exam when a child shows new distance blur. Same goes when the current prescription has changed a lot in the past year. A parent or sibling with high myopia is another trigger. Squinting or trouble reading the board at school also counts. New onset of myopia before age eight, or rapid change at any age, is a strong reason to ask about myopia control.
A child using overnight contacts who has eye pain, redness, light sensitivity, or reduced vision should be seen the same day. Microbial keratitis can progress quickly. A child using atropine drops who has ongoing redness, swelling, or itching after each dose should pause the drop and be evaluated. These are not typical adjustment symptoms.
The first myopia-control visit is longer than a routine exam. It includes cycloplegic refraction and axial biometry. It also includes a family and lifestyle history. The clinician then talks through treatment options matched to the specific child. Parents can expect to leave with a plan or a short list of options to consider.
The treatments covered here work best when started early. That means before a child has built up several diopters of myopia. Waiting until a child reaches high myopia narrows the window for meaningful slowing. Our office suggests parents of newly nearsighted children ask about myopia control at the same visit where glasses are first prescribed.
Questions Parents Ask About Myopia Control Treatment
The choice depends on the child's age, current prescription, axial length, lifestyle, family preferences, and tolerance for each option. A child who swims daily may lean toward ortho-k so the pool does not interfere with daytime contacts. A younger child who is not ready to handle contacts may start with drops or specialty glasses. The clinician lays out the trade-offs. The family then picks from the reasonable options.
Yes, most myopia-control treatments are layered on top of vision correction rather than replacing it. A child using low-dose atropine still wears regular glasses during the day for clear distance vision. A child using specialty glasses replaces the regular pair with the myopia-control pair. A child using ortho-k or soft multifocal contacts usually does not need daytime glasses while the treatment is active. The clinician explains how correction and control fit together.
Axial length is a more direct measure of the structural change that drives lifetime risk. A prescription can look stable while the eye keeps growing. Only axial biometry catches that. Tracking axial length gives a cleaner picture of whether the treatment is actually slowing the growth pattern that matters for long-term retinal health.
For a child progressing slowly with no strong family history, watchful monitoring with lifestyle reinforcement can be the right first step. For a child progressing quickly or with high-myopia parents, waiting a year lets the condition worsen in the window when treatment works best. The decision belongs to the family after the clinician has laid out both paths clearly.
Treatments can still slow progression in older children and teens. The absolute benefit tends to be smaller than in younger children, who have more growing left to do. A teen with rapid change is still worth evaluating. Every diopter avoided in the remaining growth window reduces lifetime risk. The clinician will weigh whether the expected benefit justifies the time and effort for the individual teen.
The clinician reviews adherence first. A lens not worn or a drop skipped many nights explains many apparent failures. If adherence is good and axial length is still growing quickly, options include raising the atropine strength within the studied range, switching optical strategy, or adding a second treatment. Resistance to one treatment does not mean myopia control has failed overall.
Keeping the pediatrician informed is helpful. That is especially true for children on atropine. The pediatrician is the first call if the child has an unrelated illness or medication question. A short note from the eye care office summarizing the plan can be shared at the next well visit. Coordinated care reduces the chance of conflicting guidance.
Most children continue myopia control until eye growth slows on its own. That usually happens in the mid to late teens. The exact endpoint depends on how the child's axial length trend behaves over time. The clinician talks through a tapering or transition plan as the child nears the end of active change, rather than stopping treatment abruptly.
Talk With Our Team About Myopia Control
If you have a nearsighted child and want to know which myopia control options fit your family, call our office to book a dedicated myopia management consultation. Our team will take baseline axial-length and refractive measurements, review your child's family history and lifestyle, and build a treatment plan matched to your child's specific risk profile.